At the same time, patients with KRAS gene mutations show a lower number of immunosuppressive cells in the tumor (regulatory T cells, M2 macrophages, myeloid-derived suppressor cells) than patients with KRASwt [47]. This evidence concerns the gene KRAS and neoplasm.